Island Pharmaceuticals Defends Handling of FDA Feedback in ASX Query

An announcement from Island Pharmaceuticals Ltd ( (AU:ILA) ) is now available.

Island Pharmaceuticals has responded to an ASX price query, confirming that recent feedback from the U.S. Food and Drug Administration on the development pathway for its antiviral candidate Galidesivir was materially price-sensitive. The company detailed that it received the FDA correspondence on 30 January 2026, sought expert regulatory advice to interpret the technical guidance, and then requested a trading halt on 2 February 2026 to prevent disorderly trading while preparing a market announcement.

Island explained that only its board and external advisors knew of the FDA feedback initially and that no unusual trading occurred on the day of receipt, supporting its view that continuous disclosure obligations were managed appropriately. It also disclosed that long-standing corporate advisor Ora Capital was briefed on 1 February 2026 to help prepare an investor update, highlighting the procedural scrutiny around how material regulatory information is handled and reinforcing the importance of governance in biotech market disclosures.

The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.

More about Island Pharmaceuticals Ltd

Island Pharmaceuticals is an Australian biotechnology company focused on developing antiviral treatments, including Galidesivir, targeting infectious diseases. The company is listed on the ASX and engages closely with U.S. regulators to progress its lead candidate under specialised approval pathways.

Average Trading Volume: 582,708

Technical Sentiment Signal: Buy

Current Market Cap: A$113M

Find detailed analytics on ILA stock on TipRanks’ Stock Analysis page.